Sunitinib: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

@@ Line 2: / Line 2: @@
 ===Better Known as: Sutent===
 * Marketed By: Pfizer<br />
-* Major Indication: [[Influenza]] Infection<br />
+* Major Indication: Renal Cell Carcinoma & Stomach [[Cancer]]<br />
-* Drug Class: [[M2 Proton Channel]] Inhibitor
+* Drug Class: Receptor Tyrosine Kinase (Including [[VEGFR]] & PDGFR) Inhibitor
-* Date of FDA Approval (Patent Expiration): 2006 (2001)<br />
+* Date of FDA Approval (Patent Expiration): 2006 (2020)<br />
-* 1994 Sales: N/A
+* 2009 Sales: $964 Million <ref>http://www.inpharm.com/news/101125/renal-cell-carcinoma-market-votrient-sutent</ref>
-* Importance: One of the the first treatments for [[Influenza]] Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
+* Importance:
 * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders.